Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB08915
http://purl.obolibrary.org/obo/dinto_DB08915
|
|---|---|
| Preferred Name | aleglitazar |
| Synonyms |
C24H23NO5S
(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | aleglitazar
|
|---|---|
| label | aleglitazar
|
| DBSynonym |
ro-0728804
r-1439
|
| Definition | Aleglitazar is an investigational drug from the company Hoffmann?La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPAR? and PPAR? receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.
|
| has pharmacological target | |
| activates | |
| type | |
| InChIKey | InChIKey=DAYKLWSKQJBGCS-RNZRUAGMNA-N
|
| Synonym | C24H23NO5S
(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid
|
| xref |
Wikipedia:http://en.wikipedia.org/wiki/Aleglitazar
PDB:RO7
|
| CASRN | 475479-34-6
|
| prefixIRI | obo2:dinto_DB08915
|
| related with | |
| SMILES | CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O
|
| InChI | InChI=1/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/s2
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |